AstraZeneca (AZN -0.31%) is commonly recognized as one of the most fragile Big Pharma stocks on the market. While its peers, such as GlaxoSmithKline (GSK) and Pfizer (PFE -0.17%), have restructured their R&D strategies or spun out divisions, AstraZeneca has only recently started to make changes. Last autumn, the company suspended its share-buyback program in an effort to preserve cash, reshuffled its management team, and today announced its boldest move yet: It's moving its headquarters and shifting focus to three primary R&D sites. In the following video, Motley Fool analyst Max Macaluso discusses why investors should take notice of the company's bold plans.